Canada Post Corp Registered Pension Plan Purchases 1,486 Shares of Amgen Inc. $AMGN

Canada Post Corp Registered Pension Plan raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 16.7% during the third quarter, HoldingsChannel.com reports. The firm owned 10,400 shares of the medical research company’s stock after acquiring an additional 1,486 shares during the quarter. Canada Post Corp Registered Pension Plan’s holdings in Amgen were worth $2,849,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Brighton Jones LLC lifted its stake in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares during the period. Sivia Capital Partners LLC increased its holdings in Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares during the last quarter. IFP Advisors Inc lifted its stake in Amgen by 7.0% in the second quarter. IFP Advisors Inc now owns 7,394 shares of the medical research company’s stock valued at $2,132,000 after buying an additional 483 shares during the period. 3Chopt Investment Partners LLC boosted its holdings in Amgen by 10.2% during the second quarter. 3Chopt Investment Partners LLC now owns 1,399 shares of the medical research company’s stock worth $391,000 after buying an additional 130 shares during the last quarter. Finally, First Fiduciary Investment Counsel Inc. grew its position in shares of Amgen by 6.6% during the 2nd quarter. First Fiduciary Investment Counsel Inc. now owns 17,245 shares of the medical research company’s stock worth $4,815,000 after buying an additional 1,069 shares during the period. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Saturday. UBS Group lifted their price target on shares of Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Daiwa Securities Group boosted their price target on shares of Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Deutsche Bank Aktiengesellschaft raised their price objective on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research note on Thursday. Finally, Citigroup boosted their target price on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $351.65.

Insider Transactions at Amgen

In related news, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the sale, the executive vice president owned 41,923 shares in the company, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the transaction, the senior vice president owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 10,908 shares of company stock worth $3,674,966 in the last three months. Insiders own 0.76% of the company’s stock.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Argus raised its price target to $400 and reiterated a Buy rating, signaling analyst confidence in Amgen’s outlook and providing fresh positive momentum for the stock. Read More.
• Positive Sentiment: Q4 results beat Street estimates and management’s commentary pushed the shares to a new 12‑month high — the earnings beat and upgraded FY‑2026 guidance underpin the rally. Read More.
• Positive Sentiment: Clinical progress: Amgen advanced xaluritamig into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a development that adds long‑term pipeline upside if the program shows activity. Read More.
• Positive Sentiment: Post‑marketing safety study for IMLYGIC in melanoma reached completion — reduces an uncertainty from the label/safety perspective and may support that asset’s commercial outlook. Read More.
• Neutral Sentiment: Guggenheim raised its price target to $347 but kept a Neutral rating; the new PT still implies downside versus the current price, creating mixed signals for investors. Read More.
• Neutral Sentiment: Deutsche Bank moved its target to $295 and maintained a Hold — another measured call that tempers the enthusiasm from Buy-rated upgrades. Read More.
• Neutral Sentiment: Market commentary notes rotation into defensive/health names and institutional buying as contributors to the stock’s move to multi‑month highs — a broader-market technical tailwind rather than company‑specific news. Read More.
• Negative Sentiment: CVS said it will replace Amgen’s and Lilly’s bone‑disease treatments with lower‑cost alternatives on some preferred drug lists starting April 1 — a material commercial headwind for the affected product sales. Read More.

Amgen Trading Up 4.5%

NASDAQ AMGN opened at $384.20 on Friday. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $385.12. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.99 and a current ratio of 1.14. The stock’s 50 day moving average price is $334.45 and its two-hundred day moving average price is $311.49. The stock has a market capitalization of $206.88 billion, a price-to-earnings ratio of 27.00, a PEG ratio of 3.90 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same period last year, the company earned $5.31 earnings per share. The firm’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 annualized dividend and a yield of 2.6%. Amgen’s payout ratio is presently 66.90%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.